The disclosure relates to a novel treatment of vasculitis, e.g., giant cell arteritis (GCA), polymyalgia rheumatica (PMR), Wegener's granulomatosis, polyarteritis nodosa, etc., which employs a therapeutically effective amount of an IL-17 binding molecule, e.g., an IL-17 antibody, such as the AIN457 (secukinumab)antibody, either alone or in combination (e.g., with ACZ885 (canakinumab)).